Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

July 12, 2024

Study Completion Date

July 12, 2024

Conditions
Constipation - Functional
Interventions
DRUG

CDD-2101

All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.

Trial Locations (1)

07103

Biotrial Inc, Newark

All Listed Sponsors
lead

Centre for Chinese Herbal Medicine Drug Development Limited

OTHER

NCT06570668 - Safety, Tolerability and Pharmacokinetics of CDD-2101 in Health Volunteers | Biotech Hunter | Biotech Hunter